This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Feinbloom, D. Articles by Bauer, K. A. Search for Related Content PubMed PubMed Citation Articles by Feinbloom, D. Articles by Bauer, K. A.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:e29.)
© 2006 American Heart Association, Inc.

Letters to the Editor

In Response:

David Feinbloom; Kenneth A. Bauer

Beth Israel Deaconess Medical Center, and VA Boston Healthcare System, Boston, Mass

We appreciate the comments of Boos and Lip regarding the role of other hemostatic factors in predicting arterial thrombotic events. Because of limitations in the length of our article,¹ we had to be selective in the topics that we covered and chose not to focus on markers of coagulation activation or endothelial cell damage. The former include prothrombin fragment F₁₊₂, thrombin–antithrombin complex, as well as D-dimer, while the latter include plasma von Willebrand factor (vWF) levels and soluble E-selectin. We agree that there are considerable data supporting vWF as a marker of endothelial injury as well as prospective data demonstrating that elevated vWF is associated with an increased risk for myocardial infarction after adjustment for inflammatory effects.²

In our review of hemostatic risk factors in predicting arterial thrombotic events, we primarily selected hemostatic factors that were measured in subjects at baseline rather than during an acute ischemic event. With respect to CD146-bearing circulating endothelial cells (CECs), the observations of Lee et al³ that concentrations of these cells rise in the setting of an acute coronary syndrome (ACS) and correlate with vWF are intriguing. Although statistically significant, we note that the adjusted odds ratios for elevated CECs 48 hours after clinical presentation with an ACS and major adverse cardiac outcomes at 30 days and 1 year are modest at 1.04 and 1.06, respectively.

References

1. Feinbloom D, Bauer K. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005; 25: 2043–2053.[Abstract/Free Full Text]
2. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, on behalf of the PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: The prospective epidemiological study of myocardial infarction (PRIME) study. Circulation. 2004; 109: 1343–1348.[Abstract/Free Full Text]
3. Lee KW, Lip GYH, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin (IL)-6, and prognosis in patients with acute coronary syndromes. Blood. 2005; 105: 526–532.[Abstract/Free Full Text]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Feinbloom, D. Articles by Bauer, K. A. Search for Related Content PubMed PubMed Citation Articles by Feinbloom, D. Articles by Bauer, K. A.